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Summary 
The hyaluronan  (HA)  receptor RHAMM  is an important regulator of cell growth.  Overex- 
pression of RHAMM is transforming and is required for H-ras transformation. The molecular 
mechanism underlying growth control by RHAMM  and other extracellular matrix receptors 
remains largely unknown. We report that soluble RHAMM induces Gz/M arrest by suppress- 
ing the expression of Cdc2/Cyclin B1, a protein kinase complex essential for mitosis. Down- 
regulation  of RHAMM  by use  of dominant  negative mutants  or antisense  mRNA also  de- 
creases Cdc2 protein levels. Suppression of Cdc2 occurs as a result of an increased rate of cdc2 
mRNA degradation. Moreover, tumor cells treated with soluble RHAMM are unable to form 
lung metastases. Thus, we show that mitosis is directly linked to RHAMM through control of 
Cdc2 and Cyclin B1  expression. Failure to sustain levels of Cdc2 and Cyclin B1 proteins leads 
to cell cycle arrest. 
H 
Yaluronan  (HA) 1,  a glycosaminoglycan (1),  is one of 
the  matrix  molecules  that  regulates  cell  locomotion 
via its interaction with a unique  58-70-kD cell surface re- 
ceptor for HA-mediated motility, RHAMM  (2). RHAMM 
is constitutively overexpressed in H-ras-transformed fibro- 
blasts  (2),  terminally differentiated multiple myelomas (3), 
and breast carcinoma cells. It is transiently expressed in acti- 
vated T  cells  (4)  and in bovine aortic smooth muscle cells 
after injury (5), coincident with cell locomotion. Polyclonal 
and  monoclonal  antibodies  to  RHAMM  that  block  HA 
binding to RHAMM, or peptides corresponding to its HA- 
binding domains, completely inhibit HA-induced cell loco- 
motion (2-6). Moreover, interaction of HA with RHAMM 
promotes focal adhesion  turnover and  transient phospho- 
rylation of focal adhesion kinase that leads to cell locomo- 
tion (7). 
In contrast to other extracellular matrix receptors, over- 
expression of RHAMM by transfection into nonsenescing 
fibroblasts results in elevated motility, anchorage-indepen- 
dent growth, and transformation to a fully metastatic fibro- 
sarcoma  (8).  Furthermore,  mutation  of the  HA-binding 
domains in RHAMM not only destroys its ability to trans- 
form  nonsenescing  fibroblast,  but  the  overexpression  of 
this dominant negative mutant also prevents mutant H-ras 
1Abbreviations used in this paper: GST, glutathione-S-transferase; HA, hy- 
aluronan; KBG, Kentucky Bluegrass pollen; MEF, mouse embryonic fi- 
broblast; RHAMM, receptor for hyaluronan-mediated motihty. 
transformation, indicating that HA:RHAMM signaling is on 
an essential growth regulatory pathway and downstream of 
ras (8). In this report, we examined the role of RHAMM in 
controlling cell growth by interfering with its function either 
using soluble recombinant glutathione-S-transferase (GST)- 
RHAMM fusion protein (9), or by suppressing its function 
with  either  a  dominant  negative  mutant  (8)  or  antisense 
RHAMM (8).  Our results suggest that RHAMM signaling 
controls the synthesis of Cdc2 and Cyclin B1  proteins and 
thus entry into mitosis. 
Materials and Methods 
Cell Lines.  The  CIR_A_S-3 (C3)  cell  hne  is  derived  from a 
10T1/2  fibroblast cell line  transfected  with the  H-ras and neo  R 
genes as described previously  (10). Mouse embryonic fibroblasts 
(MEFs) from  15-d-old  embryos were  kindly  provided by Dr. 
Junying Yuan  (Harvard Medical  School,  Boston,  MA).  Three 
dominant negative C3 clones (MR-C3-4D, -5B, and -5C) were 
derived  from  C3  cells stably  transfected  with  the  RHAMM 
cDNAs mutated in their HA-binding domains as described else- 
where (8). Cell lines OR1 and OR2 were derived from 10T1/2 
after stable transfection ofantisense RHAMM cDNA as described 
previously  (8). The  cells were  maintained  in  DMEM  supple- 
mented with  10% FCS.  Murine  mammary carcinoma  cell fine 
FT210, which contains a temperature-sensitive  mutation in Cdc2 
(11), was cultured as described previously (12). 
Preparation of GST Fusion Proteins.  RHAMM cDNA (2) was 
PCR-cloned into pGEX-2T plasmid as per the method described 
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len (KBG) and GST were obtained from Dr. Shyam Mohapatra 
(University  of Manitoba).  GST  fusion proteins  were  purified 
from the cell lysates by affinity chromatography using glutathione 
agarose and eluted in 50 mM Trsi-Cl, pH 8.0, containing 5 mM 
glutathione as described elsewhere (9). 
Cell Cycle Analysis.  Cells were harvested, fixed with 70% etha- 
nol,  treated  with  2N  HC1  containing 0.5%  Triton  X-100  at 
room temperature for 30 re.in, and then neutralized by treatment 
with 0.1 M  Na2B4OT, pH 8.5. Total DNA content was detected 
by propidium iodide  (PI)  staining. The  stained cells  were  ana- 
lyzed by flow cytometry using a cell sorter (Epics model 753) and 
PARA1 cell cycle analysis software (both from Coulter Electron- 
ics, Inc., Hialeah, FL). 
In  Vitro Growth Assay.  Cell density assay was  carried out by 
seeding 5  ￿  104 cells in 60-ram dishes in DMEM supplemented 
with 10% FCS. At each point, cells were harvested by trypsiniza- 
tion and viable cell concentrations were determined using trypan 
blue exclusion. 
Western Analysis.  Cells were lysed in buffer containing 50 mM 
~-glycerophosphate, pH 7.3,  1% NP-40, 10 mM NaF, 1% apro- 
tinin, and 1 mM sodium vanadate (12).  The lysates were centri- 
fuged at 30,000 g for 20 rnin at 4~  Protein concentration was 
determined by  protein  assay  kit  (Bio-Rad  Laboratories,  Rich- 
mond, CA). Lysates  were loaded at equal concentrations and re- 
solved on 10% SDS-polyacrylamide gels and transferred to nitro- 
cellulose membranes in a Tris-Cl buffer containing 25 mM Tris, 
192 mM glycine, and 20% (vol/vol) methanol, pH 8.3, at 100 V 
for 1 h at 4~  Filters were incubated with either a 1:5,000 dilu- 
tion ofpolyclonal rabbit antiserum raised against the COOH-ter- 
minal peptide (LDNQIKKM) of human Cdc2 protein (12),  or 
1 I.tg/ml ofpolyclonal rabbit antiserum raised against the COOH- 
terminal domain (287-298) of human Cdk2 (Upstate Biotechnol- 
ogy, Inc., Lake Placid, NY), or 1 p,g/ml of monoclonal anti-hu- 
man  Cyclin B1  (Upstate  Biotechnology,  Inc.)  and  developed 
with horseradish peroxidase-conjugated goat antibody to  rabbit 
or mouse IgG (Sigma Chemical Co.,  St.  Louis, MO).  Blotting 
was visualized by the enhanced chemiluminescence Western blot- 
ting system (Amersham Corp., Arlington Heights,  IL) following 
the manufacturer's instructions. 
Northern Analysis.  Total  cellular  RNA  was  extracted  by  a 
rapid RNA isolation method using Trizol reagent (GIBCO BRL, 
Gaithersburg,  MD)  as  per  the  manufacturer's instructions (13). 
For half-life measurements, transcription was inhibited after addi- 
tion of 20 I~g/ml actinomycin D for 2 h. RNA was isolated at dif- 
ferent times and 20 p,g of total cellular RNA was electrophoresed 
through  1%  formamide-agarose  gels  and  blotted  onto  Nytran 
membranes. The blots were prehybridized and probed with ran- 
dom primer 32p-labeled murine cdc2  cDNA  (provided by Paul 
Nurse,  ICI~F Cell Cycle Control Laboratory,  London, UK)  as 
described  previously  (6).  RNA  loading  was  determined  with 
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  cDNA. 
Autoradiography was analyzed by Phosphorimager SF (Molecular 
Dynamics, Sunnyvale, CA) using storage phosphorimaging. Nu- 
clear run-on assay was performed as described (14) using 32p-labeled 
RNA to probe filter-bound cdc2 and GAPDH single strand cDNA 
inserts. Quantification of transcription was determined by scanning 
phosphorimages  using Multiquant software  program  (Molecular 
Dynamics). 
Tumorigenicity and Metastasis Assay.  Cells were cultured in pres- 
ence of serum, GST protein or GST-R.HAMM for 48 h. For as- 
sessing tumorigenicity, 3  ￿  10  s viable cells were injected subcu- 
taneously into  the  right  hind leg  and  maintained for  6-8  wk 
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Figure  1.  Soluble GST-RHAMM fusion protein  in- 
hibits cell growth  by arresting cells at Gz/M.  (A) Flow 
cytometric analysis  of C3 fibrosarcoma cells in which rel- 
ative DNA content of PI-treated  cells is plotted against 
cell number. C3 cells were cultured in the absence of se- 
rum for 40 h and then incubated in 5 I~g/ml of GST- 
RHAMM or GST in 10% serum. After 48 and 72 h, cells 
were  harvested,  fixed,  and  stained  with  PI.  Growth 
curves of triplicate cultures of untreated  (O),  5 I~g/ml 
GST (I) and 5 p,g/ml GST-RHAMM (&) treated C3 
cells (B) and primary MEFs (C). C3 cells were cultured as 
in (A). MEFs were cultured in 3% serum for 24 h before 
RHAMM treatment. Live cells were counted at daily in- 
tervals and the mean values of the triplicates with stan- 
dard deviation are plotted versus time. 
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nation of the assay.  For experimental metastasis assays,  4  ￿  105 
cells were injected into the tail vein. The mice were maintained 
for  16-18 d,  euthanized, and the lungs stained by Bouins' solu- 
tion  (picric  acid,  formaldehyde,  and  acetic  acid  [15:5:1]),  and 
metastatic foci were counted under a dissecting microscope (10). 
Results  and Discussion 
Soluble RHAMM Inhibits Cell Cycle Progression.  H-ras- 
transformed  C3  fibrosarcoma  cells  (10)  were  treated  with 
GST-ILHAMM  and cell cycle progression was  monitored 
by flow cytometry. As shown in Fig.  1 A, in the presence 
of GST-R.HAMM  for 48-72 h, 48-55% of the cells accu- 
mulated  in Gz/M,  whereas  in the  presence  or  absence  of 
the  control  GST  protein,  C3  cells  cycled  normally.  No 
change in the cell cycle profile or in cell growth  (Fig.  1  B) 
was  seen  during 24  h  of RHAMM  treatment.  However, 
/LHAMM  treatment completely ablated the growth  of C3 
cells for 48-72 h  (Fig.  1 B). A  similar pattern of growth in- 
hibition was obtained with primary MEFs (Fig. 1  C). Thus, 
soluble R.HAMM  arrests  cells  at  G2/M  without  affecting 
their  progression  through  S-phase.  Although  the  mecha- 
nism by which soluble RHAMM  suppresses cell cycle pro- 
gression  is  not  known,  it  likely  interferes  with  receptor 
function because anti-RHAMM  antibody treatment of cells 
also  results  in  growth  arrest  (data  not  shown).  Similarly, 
HA-induced  cell  motility  is  blocked  by  GST-RHAMM 
fusion protein  and  antibody  (Entwhisde, J.,  B.  Yang,  C. 
Hall,  S.  Mohapatra,  A.H.  Greenberg,  and  E.A.  Turley, 
manuscript in preparation).  These  results  suggest  that  the 
tLHAMM  fusion protein blocks receptor function, possibly 
by binding to its ligand HA. 
Soluble RHAMM Suppresses Expression of Cdc2 and Cyclin 
B1 Proteins.  Since progression  through  G 2  and initiation 
of mitosis  requires  Cdc2  kinase  (15-17)  and  tLHAMM- 
treated cells arrest at G2/M, we examined the expression of 
Cdc2 protein by Western blotting. As shown in Fig.  2  A 
Figure 2.  RHAMM treatment suppresses Cdc2 and Cyclin B1 proteins. (A) RHAMM suppression of Cdc2 protein levels. C3 fibrosarcoma cells (lanes 
I-4) and primary MEFs (lanes 5-7) were cultured as in Fig. 1 and then incubated with 10 ~g/ml of either GST (lanes 2 and 6), GST linked to an unre- 
lated protein (GST-KBG)  (lane 3), or GST-RHAMM (lanes 4 and 7). After 30 h, cells were lysed and Cdc2 and Cdk2 proteins were determined by 
Western blotting (12). (B) Dose-dependent inhibition  of Cdc2 protein expression in C3 cells by GST-RHAMM. Cells were cultured as in A with the in- 
dicated dose of  proteins (Ixg/ml). Lane 1, untreated; lanes 2 and 3, GST; lanes 4 and 5, GST-KBG; lanes 6-9, GST-ILHAMM treated. (C-) Expression of 
Cdc2 and Cyclin B1 proteins in GST-R.HAMM-treated C3 cells and temperature-sensitive FT210 cells. C3 cells were cultured as in A for 5, 10, 24, and 
48 h in 10 p.g/ml GST-RHAMM before lysis. Lanes 1, 4,  7, and 10, untreated; lanes 2, 5, 8, and 11, GST treated, and lanes 3, 6, 9, and 12, GST- 
RHAMM treated. FT210 cells were cultured for 24 h at the permissive temperature of 32~  (lane 13) or the restrictive temperature  of 39~  (lane 14). 
(D) Cdc2 protein expression in cells overexpressing a dominant negative R.HAMM mutated in its HA-binding  domains. Cells were cultured overnight in 
the presence of 0.2 I~g nocodazole which arrested >85% cells at Ga/M; they were then harvested, washed three times in PBS, and lysed. Cdc2 protein 
was determined by Western blotting in parental C3 cells (lane 1), empty vector-transfected  C3 cells (lane 2), and three  C3 clones expressing mutant 
Pd-IAMM (MR-C3-4D, -5B, and -5C; lanes 3-5). (E) Cdc2 expression in 10T1/2 clones OR.1 and OR2 which over express antisense 1LHAMM and 
have 50 and 10% of control RHAMM protein levels, respectively. Cells were cultured in nocodazole and analyzed as in D. Lane 1 is a vector-transfected 
10T1/2; lane 2, clone OR1; and lane 3, clone OR.2. 
1665  Mohapatra et al. untreated cells or cells treated with GST, or GST linked to 
the unrelated KBG protein, expressed high levels of Cdc2. 
However,  after RHAMM  treatment,  Cdc2  protein levels 
drastically decreased in both in C3 cells and primary MEFs, 
whereas  Cdk2  protein  levels remained  unaffected  (Fig.  2 
A). The suppression of Cdc2 protein was dependent on the 
dose (Fig. 2  B) and the length of RHAMM  treatment (Fig. 
2  C).  No  significant reduction  in  Cdc2  protein was  seen 
before 24 h  of RHAMM  treatment. Similar results were ob- 
tained when  10T1/2,  Rat-l,  and  HeLa  cells were  treated 
with  RHAMM  (data  not  shown).  Taken  together,  these 
data strongly suggest that soluble RHAMM  arrests cells at 
G2/M by suppressing Cdc2 expression. 
We next analyzed levels of Cyclin A  and B  proteins that 
associate with  Cdc2  during entry into  G2 and mitosis, re- 
spectively. In  RdqAMM-treated  cells, the  level of Cyclin 
B1  dropped concomitantly with the Cdc2 protein 24 h  af- 
ter GST-RHAMM  treatment (Fig. 2  C) whereas the level 
of Cyclin A  remained unchanged  (data not shown).  In cy- 
cling cells, the level of Cyclin B  rises in  S  phase, peaks at 
G2/M, and drops drastically at the metaphse/anaphase tran- 
sition (18), but the level of Cdc2 normally remains constant 
throughout the cell cycle because of its relatively long half- 
life (15).  The possibility that decreased levels of Cdc2 pro- 
tein may lead to premature degradation of Cyclin B1 before 
anaphase was ruled out by the observation that suppression 
of the temperature-sensitive Cdc2 in FT210 cells (11) at re- 
strictive  temperature  did  not  alter  Cychn  B1  expression 
(Fig. 2  C-). These results suggest that treatment with soluble 
RHAMM  leads to  suppression  of Cdc2  as well as its mi- 
totic partner Cyclin B1. 
To  establish whether RHAMM  signaling is essential for 
progression  through  G2/M,  we  examined  Cdc2  protein 
levels in  several  C3  fibrosarcoma  cell  clones  that  express 
RHAMM  mutated in the HA-binding domains that acts as 
a  dominant suppressor (8).  These C3  clones, MR-C3-4D, 
-5B, and -5C, resemble nontransformed fibroblasts in their 
reduced  growth  rate  and  are  nontumorigenic  despite ex- 
pressing high levels of H-ras  (8).  Cdc2 protein levels were 
examined in  cells arrested at G2/M by nocodazole and,  as 
shown  in Fig. 2  D, the three clones bearing the dominant 
suppressor mutant of RHAMM  expressed four- to sixfold 
less Cdc2 compared with C3 parental or vector-transfected 
control  cells.  Similarly,  10T1/2  fibroblasts  that  expressed 
low levels of RHAMM  as a result of transfection and con- 
stitutive expression of antisense RHAMM  cDNA and are 
Figure 3.  RHAMM treatment increases  cdc2 mRNA degradation without altering transcription. (A) Expression of cdc2 mRNA of GST-RHAMM- 
treated C3 cells as determined by Northern blotting. Lanes 1, 2, 4, and 6 are untreated; lanes  3, 5, and 7 are RHAMM treated (10 ~g/rrd) for the indi- 
cated times. Cdc2/GAPDH ratios ￿  100 are indicated below. (B) Nuclear run-on assays. Nuclei from C3 cells were isolated after 5, 17, and 23 h of treat- 
ment with 10 Ixg/ml GST-RHAMM. 32p-labeled  RNA isolated from control (lanes 1, 2, 4, and 6) and GST-RHAMM-treated cells (lanes 3, 5, and 7) 
were used to probe nitrocellulose containing linearized cdc2 and GAPDH DNA. Cdc2/GAPDH  ratios ￿  100 are indicated below. (C') Cdc2 message 
stability  in the presence of GST-RHAMM after actinomycin D (20 I~g/ml) treatment. RNA was isolated from different samples  at the indicated time af- 
ter 2 h ofactinomycin D treatment and analyzed  by Northern blotting (12). Lanes 1-6, untreated; lanes 7-12, GST-RHAMM treated. (D) Determina- 
tion of cdc2 half-life of C3 cells in presence of GST-RHAMM, 2 h after addition of 20 I.tg/ml actinomycin D. Cdc2 half-life in untreated cells (0) is 
15 h and after RHAMM treatment (E) is 4.5-5 h. One of three experiments with similar results is shown. 
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Tumorigenicity*  Metastasis* 
Tumor latency  Tumor size (day 20)  Spontaneous  Experimental 
Treatment  (days +_ SE)  (ram  2 +- SE)  (frequency)  (lung tumors +  SE) 
Control  7 +- 1  112 +  5  8/8  >300 
GST  5 +- 0.5  136  +  17  8/8  >300 
GST-RHAMM  22 +_ 1  6 +  6  0/8  10 +- 6 
*After 48-h incubation in GST-RHAMM (10 I~g/ml), 3 ￿  105 viable tumor cells were injected subcutaneously into C3H/HeN mice. After day 
20, the tumor growth rate was equivalent to control cells. 
*Spontaneous metastases were assessed in mice 8 wk after receiving subcutaneous tumor. Experimental lung metastases were examined 21 d after in- 
travenous injection of 4 X 10  s viable cells. 
resistant  to  H-ras  transformation  (8),  also  have  reduced 
Cdc2 protein levels (Fig. 2 E). Taken together, these results 
indicate that HA:RHAMM-mediated  signaling is necessary 
for maintenance of Cdc2 protein levels. 
Soluble RHAMM Increases cdc2 mRNA  Degradation Rate. 
In  cycling  cells,  Cdc2  protein  levels  are  maintained  at  a 
nearly  constant  steady-state  level,  however  cdc2  mRNA 
synthesis is initiated during each cell cycle beginning at the 
G1/S  transition  reaching  a  maximum  at  G2  (19,  20).  As 
shown in Fig.  3  A,  an increase in cdc2 mRNA  levels was 
seen in control C3 cells after serum stimulation.  However, 
5  h  after  treatment  with  RHAMM  in  the  presence  of 
serum,  cdc2  mRNA  levels  of C3  cells  decreased,  and  by 
17-24 h  of treatment,  a greater than  10-fold reduction was 
seen. Nuclear run-on assays performed with C3 nuclei pre- 
pared  from  cells  cultured  in  the  presence  or  absence  of 
RHAMM  revealed  no  change  in  transcription  of  cdc2 
mRNA  that  could  account  for the  reduced  levels  (Fig.  3 
B). To explore the alternative possibility that RHAMM  al- 
ters  cdc2  mRNA  degradation  rates,  we  next  determined 
the  mRNA  half-life by examining RNA  levels  over time 
after  treatment  of C3  cells  with  actinomycin  D.  In  the 
presence  of RHAMM,  the  cdc2  mRNA  half-life was re- 
duced to 4.5-5  h  from the normal 15 h  (Fig.  3,  C  and D). 
These  results  indicate  that  soluble  RHAMM  suppressed 
Cdc2  protein and RNA  expression by increasing the  deg- 
radation rate of cdc2 mRNA. 
Soluble  RHAMM  Inhibits  Tumorigenicity  and  Metastasis. 
We  have previously  shown  that  HA:RHAMM  signaling 
is  essential  for  H-ras  transformation  (8).  In  the  present 
study  we  wanted  to  determine  if suppression  of signaling 
induced  by soluble  RHAMM  reduced  the  tumorigenicity 
and  metastatic  ability  of C3  fibrosarcomas  (10).  Mice  re- 
ceiving 3  ￿  105 viable cells subcutaneously  after treatment 
with  RHAMM  for 48  h  in vitro  developed subcutaneous 
tumors that were smaller and appeared later than  controls, 
and no spontaneous metastases were observed in these mice 
(Table 1). Moreover, after intravenous injection, RHAMM- 
treated cells formed very few lung nodules  (10/lung)  com- 
pared with both control groups (>300/lung).  These results 
suggest that soluble RHAMM  can suppress receptor signal- 
ing and tumorigenicity similar to altering receptor function 
(8). It is also possible that tumor cells that were treated with 
soluble RHAMM  failed either to migrate through extracel- 
lular matrix or to interact with HA at a distant site, and thus 
inhibited  metastasis.  A  similar approach  has been  used  for 
CD44,  another  HA receptor,  in which  infusion  of soluble 
CD44H-Ig fusion protein inhibited metastasis (21, 22). 
Our study indicates  that RHAMM  signaling may coor- 
dinately regulate the synthesis of Cdc2 and the detachment 
required  for  cells  to  enter  mitosis.  The  synthesis  of HA, 
which is the RHAMM  ligand, has been correlated to many 
cellular functions  including  cell proliferation and cell divi- 
sion  (1).  In particular,  HA  synthesis  and  synthase  activity 
increase  during  mitosis  when  cells  round  and  are  loosely 
adherent,  possibly because  HA is required  for detachment 
of cells from the supporting  matrix (23).  Synergistic inter- 
actions between  growth factors and integrin-mediated  sig- 
nal transduction  involving sustained tyrosine phosphoryla- 
tion regulate  cell proliferation and cell adhesion  during G 1 
to  S  transition  (24-27)  and  Cyclin A  expression  has been 
shown  to be  a  target for adhesion-dependent  signals  (28). 
In  contrast,  HA:RHAMM  interactions  that  involve  rapid 
but  transient  tyrosine phosphorylation  and promote  dead- 
hesion (7) may be required specifically during G2/M transi- 
tion where increased HA synthesis occurs (23). Thus, Cdc2 
seems  to  be  a  target  of  RHAMM-mediated  signaling 
events at mitosis. Whether Cyclin B1  is directly suppressed 
by RHAMM  or occurs secondary  to suppression  of Cdc2 
remains to be elucidated. 
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